NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 11th July 2024

**Location:** Via London Office and Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Anna Pracz Present for all items
3. Dr Alistair Patton Present for all items
4. Dr Bushra Hasnie Present for all items
5. Dr Daniel Gallacher Present for all items
6. Dr Francis Drobniewski Present for all items
7. Dr Hatim Abdulhussein Items 1.1 to 4.2.2
8. Dr Mark Tanner Items 1.1 to 4.2.2
9. Dr Natalia Kunst Present for all items
10. Dr Rhiannon Owen Items 1.1 to 4.2 /

Present for all items

1. Dr Toby Smith Present for all items
2. Gabriel Rogers  Present for all items
3. Giles Monnickendam Present for all items
4. Lisa Attrill Present for all items
5. Professor David McAllister Present for all items
6. Stella O’Brien Present for all items
7. Tony Wootton Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director

Rich Diaz, Associate Director Items 1.1 to 5.2.2

Vonda Murray, Project Manager Items 1.1 to 5.2.2

Claire Hawksworth, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Emilene Coventry, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Michelle Green, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Raphael Egbu, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Emily Crowe, Associate Director Items 6.1 to 6.2.2

Jeremy Powell, Project Manager Items 6.1 to 6.2.2

Adam Brooke, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Emma McCarthy, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Sam Bryning, Liverpool Reviews and Implementation Group (LRIG)

Items 1.1 to 4.1.3

Janette Greenhalgh, Liverpool Reviews and Implementation Group (LRIG)

Items 1.1 to 4.1.3

David Cooper. Aberdeen HTA Group Items 5.1 to 5.1.3

Dwayne Boyers, Aberdeen HTA group Items 5.1 to 5.1.3

Dwayne Boyers, Aberdeen HTA group Items 6.1 to 6.1.3

Dolapo Ayansina, Aberdeen HTA Group Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Peter Clark, National Cancer Drugs Fund Clinical Lead Present for all items

Richard Adams, Consultant Clinical Oncologist, Velindre University NHS Trust, clinical expert nominated by Seagen Items 1.1 to 4.1.3

Mark Saunders, Consultant Clinical Oncologist, The Christie, clinical expert nominated by NICE Items 1.1 to 4.1.3 (3 topics)

Mark Saunders, Consultant Clinical Oncologist, The Christie, clinical expert nominated by Takeda Items 5.1 to 5.1.3

Mark Saunders, Consultant Clinical Oncologist, The Christie, clinical expert nominated by Servier Laboratories Items 6.1 to 6.1.3

Harpreet Wasan, Consultant & Professor in Oncology & Lead for Medical oncology, Clinical expert nominated by Takeda Items 5.1 to 5.1.3

Harpreet Wasan, Consultant & Professor in Oncology & Lead for Medical oncology, Clinical expert nominated by NICE Items 6.1 to 6.1.3

Steve Bennett, Patient expert nominated by GUTS UK Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Baljit Singh, Vanessa Danielson, Veline L’Esperance, Andrew Makin, Nigel Westwood, Peter Wheatley-Price, Warren Linley, and Stuart Williams.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 13th June.

1. **Appraisal of** [**Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta11228)
   1. Part 1 – Closed session
      1. The chair welcomed the invited experts, external assessment group representatives, and company representatives from Pfizer.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11228).
      3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tony Wootton (lay), Hatim Abdulhussein (clinical) and Daniel Gallacher (cost).
   2. Part 2 – Closed session (company representatives, clinical experts, and external assessment group representatives were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11228>.

1. **Appraisal of** [**Fruquintinib for previously treated metastatic colorectal cancer [ID6274]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta11280)
   1. Part 1 – Closed session
      1. The chair welcomed the invited experts, external assessment group representatives, and company representatives from Takeda.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11280).
      3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee Tony Wootton (lay) Anna Pracz (clinical) and Gabriel Rogers (cost).
   2. Part 2 – Closed session (company representatives, clinical experts, and external assessment group representatives were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11280>.

1. **Appraisal of** [**Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta11390)
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Servier.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11390).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
   2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11390>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 14th August and will start promptly at 9:00am.